Successful early-stage innovation deals: Pharma and biotech partners divulge specifics

Edition

Successful early-stage innovation deals: Pharma and biotech partners divulge specifics

What are pharma companies awaiting from the start-ups they would like to interact with?
Learn from success stories of pharma-biotech collaborations through successful deals they made. What were the hurdles to these deals? What are the keys to carry a good partnership? What are the factors of success and how to handle them? When is it the best time to go meet with pharma for a biotech start-up?

Learn from figures and statistics: how many people get a deal at the end? How to picture an innovation in the best possible way to make a deal? How interactions between early-stage projects and pharma help anticipate pitfalls at the very early development stages? How innovative products have proven to come out of these deals?

This session advocates that a problem shared is a problem solved.

Gerald Law

Chief Executive
United Kingdom
Innovation DB

Loic Lhuillier

Chief Operating Officer
United Kingdom
Exonate Ltd

Jochen Maas

General Manager R&D Germany
Germany
Sanofi

Shane Maloney

Global Head of Transactions
France
Servier

Luc Boblet

Founder and CEO
France
Egle Therapeutics

Phil L’Huillier

Head of Business Development, Europe
United Kingdom
MSD
Scroll to Top
  • No products in the cart.